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S U M M A R Y
Background: Crimean-Congo hemorrhagic fever (CCHF) is a virulent tick-borne disease reported in more
than 30 countries across Europe, Africa, and Asia. The disease is considered endemic in several Central
Asian countries, including Tajikistan; however reports of human cases from these regions rarely reach
the West.
Methods: We analyzed all historical conﬁrmed cases of CCHF in Tajikistan, mapping these reports
against geographic data to assess risk areas. In addition, comprehensive analysis was undertaken on the
2010 human CCHF cohort to demonstrate effective methodologies for diagnosing this disease in-country.
Results: These data show that CCHF is endemic in Tajikistan, and several large clusters have been
recorded. Endemic foci of disease are localized to the southern region, with geographical factors such as
altitude, monthly mean temperature, and monthly mean precipitation levels limiting establishment of
tick vectors in other areas. Genomic analysis of viral RNA from a 2010 human case revealed high
nucleotide homology (99%) to a strain isolated in Tajikistan in 1990.
Conclusions: CCHF is an important vector-borne and nosocomial pathogen in Tajikistan. The ability to
rapidly detect cases using real-time RT-PCR shortly after admission in the hospital setting allows prompt
implementation of barrier nursing techniques, therefore reducing onward transmission of the virus.
Crown Copyright  2013 Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Crimean-Congo hemorrhagic fever (CCHF) is a virulent tick-
borne human disease caused by a single-stranded, negative sense
RNA virus classiﬁed within the Nairovirus genus of the family
Bunyaviridae. The viral genome is comprised of three distinct
segments: a small (S) segment encoding the nucleocapsid protein,
a medium (M) segment encoding the two structural membrane
glycoproteins Gn and Gc, and a large (L) segment encoding the
RNA-dependent RNA polymerase. The CCHF virus (CCHFV) is
maintained in nature in an enzoonotic cycle involving a variety of
non-human vertebrate species, with animal-to-animal transmis-
sion mediated by ticks. Both vertebrate hosts and tick vectors act as
reservoirs of viral infection. Transmission to humans can occur
through bite from an infected tick, or contact with infected tissues
(e.g., butchery or surgery).* Corresponding author. Tel.: +44 0 1980 612951.
E-mail address: barry.atkinson@phe.gov.uk (B. Atkinson).
1201-9712/$36.00 – see front matter . Crown Copyright  2013 Published by Elsevier 
http://dx.doi.org/10.1016/j.ijid.2013.04.008With the exception of suckling mice, humans appear to be the
only host species to display clinical signs of disease upon infection
with CCHFV.1 Disease progression is well documented and typiﬁed
by four distinct phases: incubation, prehemorrhage, hemorrhage,
and, for patients who survive, convalescence. The asymptomatic
incubation phase typically lasts 1–6 days, leading to a prehemor-
rhage phase characterized by the sudden onset of fever (usually
39–41 8C), chills, headache, and nausea. There is a rapid progres-
sion to the hemorrhagic stage, initially manifesting with petechiae,
which merge into ecchymoses. Wider hemorrhagic symptoms
have been reported, especially bleeding from the nose and gums,
but often involving the gastrointestinal, urinary, and respiratory
tracts. In non-fatal outcomes, convalescence is deﬁned when
hemorrhagic manifestations resolve and patients gradually recov-
er. It can take several weeks for typical body indices to be restored.
In addition to this long recovery period, there are reports of long-
term sequelae including impaired vision and neurological pro-
blems, although these are rarely permanent.1–3
General supportive therapy and ﬂuid replacement is the
mainstay of patient management in CCHF infections. IntensiveLtd on behalf of International Society for Infectious Diseases. All rights reserved.
B. Atkinson et al. / International Journal of Infectious Diseases 17 (2013) e1031–e1037e1032monitoring to guide volume and blood component replacement is
required. Many countries, including Tajikistan, recommend
ribavirin for conﬁrmed cases of CCHF; however the beneﬁt of this
regimen is still unclear and remains in debate.4–7 This is
compounded with a cost burden for the patient associated with
administration (estimated at 100 USD per patient course). A
vaccine based on a formalin inactivation of CCHFV grown in the
suckling mouse brain was developed in the former Soviet Union in
the late 1960s.8 Although the vaccine has been used for high risk
groups in Bulgaria since 1974, data regarding vaccine efﬁcacy have
not been published, and the vaccine is not widely used outside of
Bulgaria.
Several scholarly texts dating back as far as the 12th century
make reference to human disease with hemorrhagic symptoms
associated with ticks circulating in the region that is present-day
Tajikistan,9,10 although the ﬁrst full medical description of CCHF
was not made until 1944 following a large outbreak of severe
hemorrhagic fever in Crimea.11 Since this initial identiﬁcation,
cases of CCHF have been conﬁrmed in more than 30 countries
across Asia, Africa, and Europe.12 Importantly, CCHFV is an
emerging virus, appearing in new populations and increasing its
geographic range with recent clinical reports from Sudan, Kenya,
Turkey, India, Greece, and Georgia.13–18 Furthermore, molecular
detection of CCHFV RNA has recently been reported in Spain,
although to date no cases of human disease have been recorded
in this region of Europe.19 Conﬁrmed imported cases of CCHF
from endemic countries have been documented in both France
and the UK.20,21
Human cases of CCHF have been ofﬁcially documented in
Tajikistan since formal identiﬁcation of the disease in 1944. The
methods for conﬁrming cases of CCHF have evolved due to
technological and scientiﬁc advances. Prior to the development of a
diagnostic complement ﬁxation assay,22 conﬁrmation of CCHF
cases in Tajikistan was based solely on clinical presentation of the
disease. While the complement ﬁxation test provided an important
bedrock of CCHF diagnosis, this assay was difﬁcult to control and
standardize, and suffered from relatively poor levels of sensitivi-
ty.23 The complement ﬁxation assay formed the primary diagnostic
tool until cheap, easy to use, and reliable commercial serological
assays were introduced into routine local laboratory use in 1993.24
These IgM and IgG tests remain a frontline methodology for
detecting cases of CCHF in Tajikistan, although in recent years this
technology has been supplemented with speciﬁc RT-PCR and real-
time RT-PCR assays. In this report we summarize previously
unreported historical cases of CCHF in Tajikistan and provide
detailed analysis of more recent cases.Table 1
Primers used for RT-PCR ampliﬁcation and sequence analysis
Primer Name Sequence (50 to 30 orientation) 
CCHF S Terminal R TCTCAAAGAAACACGTGCCGC 
CCHF S Terminal F TCTCAAAGATAYCGTTGCCGCA 
CCHF S 1668 F AAGATAYCGTTGCCGCACA 
CCHF S 1148 R GCHGATGAYTCTTTCCAGSARAACAG 
CCHF S 777 F GTTTCTGCGAGTTTGGCAAG 
CCHF S 1011 F ACGCCKGCTTTGTAGAGCCAGTA 
CCHF S 1129 F CTTCTTTCCCCACTTCATTGG 
CCHF S 1354 F CAACTTGACAATKGTCTTGGCACA 
CCHF S 553 F GACAGACATYACAATYTCRCCAGG 
CCHF S 653 R TGGTGTAGGGAGTTTGTCAAGGG 
CCHF S 733 R AGGAATAGCACTTGTTGCAACAG 
CCHF S 1112 R ATGAAGTGGGGGAAGAAGCTYTATG 
CCHF S 1158 R TCCAGSAGAACAGGATYTAYATGC 
a Based on Baghdad 12 strain (GenBank accession AJ538196).
b All primers can be used for classic RT-PCR ampliﬁcation in order to detect CCHFV.
c Used to generate overlapping sequence data from the 1.7 kilobase amplicon produ2. Materials and methods
2.1. Samples
Serum samples from suspected human cases of CCHF in
Tajikistan were sent to the Science and Research Institute of
Preventive Medicine (SRIPM) in Dushanbe. Blood samples were
divided into two aliquots, one chemically inactivated for molecular
techniques and the other heat inactivated for serological techni-
ques. Chemical inactivation was achieved using AVL buffer
(Qiagen), and viral RNA was puriﬁed using the QIAamp Viral
RNA Mini Kit (Qiagen) in accordance with the manufacturer’s
instructions. Thermal inactivation was achieved by heating patient
serum samples to 60 8C for 1 h.25
2.2. Serology
Commercial CCHF IgM and IgG ELISA kits (Ivanovsky Institute
and Vector-Best) were utilized to assess the immunological status
of patient samples, in accordance with the manufacturer’s
instructions.
2.3. Molecular detection
Puriﬁed RNA was analyzed using a real-time RT-PCR assay
targeting the highly conserved terminal regions that form the pan-
handle loop structure of the CCHFV S segment26 on the
MiniOpticon real-time platform (BioRad).
Classic RT-PCR was performed on real-time positive samples
using the PCR primers described in Table 1. The two terminal
primers were designed to bind to the extreme terminal sequences
of the CCHFV S segment genome and amplify the entire S segment
(approximately 1.7 kilobases). RT-PCR ampliﬁcation was per-
formed using SuperScript III One-Step RT-PCR System with
Platinum Taq (Invitrogen). The ﬁnal mastermix (50 ml) comprised
25 ml of 2  Reaction Mix, 14 ml of PCR-grade water, 2 ml of each
primer (at 10 mM working concentration), 2 ml of SuperScript III
RT/Platinum Taq Mix, and 5 ml of template. The cycling conditions
used were: 50 8C for 10 min, 95 8C for 2 min, followed by 45 cycles
of 95 8C for 15 s, 57 8C for 30 s, and 68 8C for 1 min 45 s, and a ﬁnal
extension step of 68 8C for 7 min. Bands of interest were excised
from 2% agarose gel, and puriﬁed using the QIAquick Gel Extraction
Kit (Qiagen) in accordance with the manufacturer’s instructions.
Sequence analysis was performed at the Health Protection
Agency, Porton Down, UK, using the same terminal consensus
primers used to produce the amplicon, as well as additionalStrand Positiona Use in studyb
Sense 1 RT-PCR & sequencing
Antisense 1673 RT-PCR & sequencing
Antisense 1668 RT-PCR & sequencing
Sense 1148 RT-PCR & sequencing
Antisense 777 Sequencingc
Antisense 1011 Sequencingc
Antisense 1129 Sequencingc
Antisense 1354 Sequencingc
Antisense 553 Sequencingc
Sense 653 Sequencingc
Sense 733 Sequencingc
Sense 1112 Sequencingc
Sense 1158 Sequencingc
ced by the CCHF S terminal primers.
Figure 1. Human cases of CCHF in Tajikistan from 1943 to 2009 plotted against elevation.
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fragment. Nucleotide labeling was carried out using the Big Dye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems),
unincorporated dye terminator was removed using the DyeEx
2.0 Spin Kit (Qiagen), and sequencing of products was carried out
on a 3130xl sequencer (Applied Biosystems), all performed in
accordance with the manufacturer’s instructions.
2.4. Environmental analysis
Environmental data were obtained from DIVA-GIS, an online
portal providing access to software and datasets for environmental
analysis from various data providers.
Elevation data were supplied by the International Centre for
Tropical Agriculture (CIAT) derived from NASA Shuttle Radar
Topographic Mission (SRTM) data, a 90m Digital Elevation Model
(DEM). The SRTM dataset is not a continuous global DEM, and CIAT
processes the data to ﬁll the gaps using spatial interpolation
techniques.27
Climate data were obtained from WorldClim – interpolated
representations of global climate variables derived from climate
observation stations between 1950 and 2000.28 Each WorldClim
variable was structured as 12 monthly grids representing monthly
averages at approximately 1-km grid resolution.
The source CCHF case dataset includes latitude/longitude in
decimal degrees based on reporting district. CCHF cases were
represented as annual counts of cases for 26 locations in Tajikistan
between 1943 and 2009, and a cumulative total of cases for the
same period. The human CCHF case locations were georeferenced
using the latitude/longitude and mapped using ArcGIS Desktop
software. Proportional symbolization was then used as the most
appropriate method for representing the quantity of total cases per
location.Elevation and climatic data were downloaded in grid (*.grd)
format and DIVA-GIS software was used to translate them into ESRI
ASCII format. The elevation data were processed into a single ESRI
ASCII grid for Tajikistan and used as a contextual basemap for
Figure 1. Mean monthly precipitation and temperature data were
translated into ASCII grid format using DIVA-GIS translation tools.
The ArcGIS Spatial Analyst Map Algebra geoprocessing tool was
then used to calculate the annual mean monthly temperature and
precipitation grids used for Figures 2 and 3.
3. Results
3.1. Historical data
The SRIPM in Dushanbe is the national reference laboratory for
human cases of CCHF in Tajikistan. Up to and including 2009, a
total of 430 conﬁrmed human cases of CCHF have been recorded in
Tajikistan (Table 2). The earliest cases (1943) represent retrospec-
tively ascribed cases following publication of medical symptoms
after identiﬁcation of the disease. There is an apparent increase in
cases through the decades, although this is likely due to an
increased disease awareness combined with improved methodol-
ogies for diagnosis and conﬁrmation.
Table 3 documents the occurrence of CCHF disease clusters (for
this particular instance, the term ‘cluster’ is deﬁned as ﬁve or more
conﬁrmed human cases within the same administrative district
within a calendar year). While the majority of CCHF cases in
Tajikistan were as a result of a bite from an infected tick, clusters
were typically as a result of either exposure to infected animal
blood products such as communal butchering of animals, or
nosocomial/close-contact transmission. As with the increase in
overall human cases, there is an apparent increase in cluster
Figure 2. Human cases of CCHF in Tajikistan from 1943 to 2009 plotted against monthly mean temperature.
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underlying effects impact upon these data.
3.2. Environmental data analysis
Geographically, Tajikistan can be divided into three areas: the
northern region, the southern region, and the eastern region
(almost entirely comprised of the Pamir Mountain range). The
country is mountainous with the majority of the eastern region
greater than 4000 metres above sea level, and areas less than 1000
metres above sea level only occur in the extreme northern and
southern regions of the country. Plotting coordinates of reported
CCHF cases against topographic and meteorological data for
Tajikistan shows a clear risk area associated with the southern
region (Figures 1–3). This is probably due to the route of exposure;
in Tajikistan the majority of human cases are a direct result of a bite
from an infected tick. Hyalomma anatolicum appears to be the
principle vector in Tajikistan, accounting for over 82% of ticks
collected in endemic areas.29,30 Other potential vector species have
been recorded including Hyalomma marginatum, Hyalomma
scupense (formerly Hyalomma detritum), Hyalomma impeltatum,
Hyalomma dromedarii, Hyalomma turanicum, and Dermacentor
marginatus, although their role in enzootic cycles is unknown and
requires further study. H. anatolicum is a tick species that prefers
drier and warmer conditions than the common vector species in
Eurasia, H. marginatum. It is not therefore surprising to ﬁnd CCHF
cases concentrated in the warmer and drier south of the country. It
is however interesting to note that the extreme northern areas of
Tajikistan have similarities in regard to elevation, monthly mean
temperature, and monthly mean precipitation to the CCHF
endemic regions of the south, yet no human cases have been
reported from these regions to date. Data regarding the distribu-
tion of potential tick vectors in this northern region are limited,although anti-CCHFV antibodies have been detected in cattle from
this locality.31
3.3. 2010 cohort
Samples from seven suspected clinical cases of CCHF were
provided for analysis, as well as samples from four close contacts of
these patients (Table 4). Real-time RT-PCR analysis conﬁrmed the
presence of CCHFV in ﬁve of the seven suspected cases (with no
CCHFV detectable in the other two suspected cases), and conﬁrmed
the absence of CCHFV in all four contact cases.
Serological analysis for the seven suspected CCHF cases
produced a similar diagnosis, although there were two minor
discrepancies: patients 3 and 6 tested negative via real-time RT-
PCR, but both patients tested positive for CCHFV IgM and IgG
antibodies. The presence of IgG antibodies in both patients may
indicate that the disease was well progressed, and that both
patients may have cleared the CCHFV (patient 6 had made a
complete recovery before blood samples were taken for analysis).
There was also one minor discrepancy among the contact samples;
contact 3 had detectable levels of IgM, but undetectable levels of
IgG, no evidence of viral RNA, and no clinical symptoms of disease.
3.4. Sequence analysis
Sequence analysis of viral RNA extracted from the serum
sample of patient 4 produced a 1449-base pair contiguous
fragment of the CCHFV S segment. This amplicon encompassed
the entire nucleocapsid protein open reading frame and represents
87% of the CCHFV S segment with only the terminal 50 and 30
sequences unresolved. BLAST analysis (NCBI) showed that the
sequence groups with the Asia 2 clade of CCHFV;32 the closest
known sequence was determined to be a strain of CCHFV identiﬁed
Figure 3. Human cases of CCHF in Tajikistan from 1943 to 2009 plotted against monthly mean precipitation.
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(GenBank accession number JN086996) differed by 19 point
mutations from the 1990 Tajik strain across the 1449-base pair
region; the majority of these mutations are silent and result in just
two amino acid changes.Table 2
Conﬁrmeda human cases of CCHF in Tajikistan from 1943 to 2009
Location GPS 1943–1949 1950–1959 1960–196
Baljuvon 3831N, 6967E 0 0 0 
Dangara 3810N, 6934E 0 2 8 
Dushanbe 3854N, 6878E 4 0 0 
Faizobod 3855N, 6932E 0 0 0 
Farkhor 3750N, 6940E 1 3 0 
Hisor 3853N, 6855E 0 0 2 
Kolkhozobod 3759N, 6866E 0 1 0 
Kulob 3791N, 6978E 0 2 0 
Kuybyshevsk 3787N, 6873E 0 4 2 
Moskovskiy 3766N, 6963E 0 15 1 
Nurak 3838N, 6932E 0 0 2 
Obikik 3816N, 6867E 0 0 0 
Panj 3724N, 6910E 5 8 1 
Qabodiyon 3748N, 6832E 0 0 0 
Qumsangir 3747N, 6864E 0 0 0 
Qurghonteppa 3784N, 6878E 4 0 0 
Sarband 3787N, 6892E 0 0 0 
Shaartuz 3727N, 6813E 0 0 2 
Somoniyon 3844N, 6878E 1 0 3 
Temurmalik 3803N, 6958E 1 0 6 
Tursunzoda 3850N, 6822E 0 0 7 
Vahdat 3855N, 6902E 0 0 2 
Vakhsh 3771N, 6883E 2 0 0 
Vose’ 3780N, 6964E 0 1 1 
Yavan 3831N, 6904E 0 0 1 
Total 18 36 38 
a Conﬁrmation based upon clinical presentation, complement ﬁxation, serological as4. Discussion
There is evidence that CCHFV has been circulating and causing
disease in the area now recognized as Tajikistan for nearly 1000
years. The cases presented here demonstrate that this disease is9 1970–1979 1980–1989 1990–1999 2000–2009 Total
0 0 10 23 33
3 7 24 47 91
0 0 0 6 10
0 0 0 2 2
1 0 0 0 5
1 1 0 0 4
0 0 0 0 1
0 0 0 7 9
1 0 1 1 9
0 0 0 0 16
0 0 0 0 2
0 0 0 4 4
0 0 0 0 14
0 0 3 2 5
0 0 0 1 1
1 2 0 2 9
0 0 2 0 2
0 0 14 1 17
8 12 9 16 49
11 3 3 31 55
2 2 13 17 41
0 0 0 24 26
0 0 0 0 2
0 0 1 2 5
3 12 2 0 18
31 39 82 186 430
says and/or molecular assays.
Table 3
CCHF clusters in Tajikistan resulting in ﬁve or more conﬁrmed cases (1943–2009)
Year Location Cases
1947 Panj 5
1951 Moskovskiy 6
1956 Moskovskiy 6
1967 Dangara 5
Tursunzoda 7
1973 Temurmalik 5
1987 Somoniyon 9
Yavan 12
1991 Shaartuz 8
1993 Tursunzoda 6
1995 Shaartuz 5
1997 Baljuvon 9
Dangara 6
2001 Baljuvon 8
Dangara 10
Temurmalik 6
2002 Baljuvon 6
Dangara 8
2003 Dangara 9
2004 Dangara 5
2006 Temurmalik 5
2007 Dushanbe 5
Temurmalik 5
Vahdat 8
2008 Dangara 6
Temurmalik 5
Vahdat 16
2009 Tursunzoda 15
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Collated data regarding the incidence of disease in Tajikistan imply
that the number of human cases reported is on the increase.
Collated data regarding the incidence of disease in Tajikistan
indicates that the number of human cases detected is on the
increase; however, it is important to recognize that raised
awareness of this disease and improved diagnostics are likely to
contribute to this increase.
The ability to accurately detect human cases of CCHF is critically
important. Laboratory conﬁrmation of disease allows implemen-
tation of appropriate barrier nursing techniques in order to prevent
further transmission of the virus. Assessment of the cases provided
from 2010 shows that a combination of clinical evaluation and
molecular assays should be adopted when making patientTable 4
Case information of human samples provided for CCHFV analysis; all samples taken in
Exposure Symptoms 
Patient 1 Exposure to infected animal blood SHF 
Patient 2 Tick bite or exposure to infected animal blooda SHF 
Patient 3 Tick bite SHF 
Patient 4 Tick bite SHF 
Patient 5 Tick bite Mild fever 
Patient 6 Probable tick bite SHF 
Patient 7 Tick bite SHF 
Contact 1 Son of patient 1 None 
Contact 2 Nurse of patient 2 None 
Contact 3 Son of patient 5 None 
Contact 4 Nurse of patient 6 None 
SHF, severe hemorrhagic fever; CCHF, Crimean-Congo hemorrhagic fever.
a Patient initially reported tick bite, however follow-up investigation also showed re
b Multiple samples tested: only samples taken 10 days after onset of symptoms pos
c Presence of IgG antibodies indicates viral infection was not recent, and may explai
d Weak signal: given presence of IgG antibodies, this could indicate viremia is contr
e Only a mild fever reported. Patient only tested for CCHF due to potential exposure vi
Tajikistan.24
f Only samples taken after recovery from disease available for testing. The immune re
have been cleared from the body.
g Multiple samples tested: samples taken 10 days after onset of symptoms tested ndiagnoses, and that serological assessment can prove useful for
retrospective screening. Clinical evaluation has the potential to
provide the easiest and most time-efﬁcient method of identiﬁca-
tion; however, this is complicated by the variable clinical
presentations of CCHF, especially in the early stages of disease.
Importantly, other infections such as typhus, malaria, leptospiro-
sis, and other non-CCHFV arboviruses need to be considered as part
of the differential diagnosis. Real-time RT-PCR offers the most
sensitive form of detection to corroborate an initial clinical
evaluation. Although it can be costly to perform and is dependent
upon the presence of viral RNA in patient samples, which decreases
rapidly after the onset of symptoms,35 it is nevertheless critical in
deﬁning a CCHF diagnosis at an early stage when patients are still
infectious and pose a serious risk to medical staff. Analysis of
patient antibody levels using serological techniques can be
beneﬁcial, especially for retrospective analysis, due to ease of
use and speciﬁcity. However, reactive antibodies are not produced
until approximately 1 week after the onset of symptoms, and are
often absent in patients who progress to a fatal outcome.36 Given
the propensity for nosocomial transmission of CCHF, serological
testing alone should not be relied upon in the clinical setting.
Nevertheless, all three methodologies when used in combination
allow for precise identiﬁcation of the clinical status and history of
each patient, reducing the possibility of misdiagnosis.
The analysis of the clinical samples documented in this report
shows that a strain of CCHFV similar to that isolated in the 1990s is
circulating in Tajikistan.
CCHFV has previously been detected in ticks from all non-
mountainous regions of Tajikistan;37 however, to date, cases of
human disease have only been detected in the south. Based on
current GIS analysis, it would appear that conditions in the
extreme northern regions of the country, where there have yet to
be conﬁrmed CCHF cases reported, are similar to those in the south.
The lack of CCHF cases in the extreme northern regions may be due
to a reduced awareness in this region, a lack of enzootic hosts,
reduced livestock numbers, and/or reduced human interaction
with ticks in this area. Based on these ﬁndings, future ﬁeld work
will aim to address the focal endemic ecology of CCHFV in the
north. This will help determine differences in tick/reservoir host
species and densities between the north and south regions, and
may contribute to disease control strategies in the future.
As well as vector-borne transmission, CCHFV has the potential
for nosocomial spread, and several recent clusters of CCHF in 2010
IgM IgG Real-time RT-PCR Diagnosis
+  + CCHF
+ b + CCHF
+ + c CCHF
+ + +d CCHF
+  + Mild/asymptomatic CCHFe
+ + f CCHF
+ +b +g CCHF
   No infection
   No infection
+   Mild/asymptomatic CCHF?
   No infection
cent exposure to animal blood through butchery of cows.
itive via IgG analysis; earlier samples only showed IgM positivity.
n lack of viral RNA.
olled.
a tick bite. Asymptomatic cases of CCHF have been reported on several occasions in
sponse is still detectable, however real-time RT-PCR is negative as the virus would
egative via real-time RT-PCR.
B. Atkinson et al. / International Journal of Infectious Diseases 17 (2013) e1031–e1037 e1037Tajikistan have resulted in transmission of the virus in the hospital
setting.24 It is important, therefore, that the healthcare system is
adequately prepared to: (1) recognize symptoms of CCHF disease,
(2) immediately impose necessary barrier nursing techniques, (3)
send suspected positive samples to the national CCHF reference
laboratory in Dushanbe, and (4) monitor potentially exposed
individuals. The SRIPM in Dushanbe has over 50 years of active
experience with CCHF diagnosis, with recent international
collaborations furnishing the laboratory with modern diagnostic
techniques. This capability is helping disseminate up-to-date
information to regional hospitals in high-risk areas. Signiﬁcantly,
this raises awareness and better capacity for infection control in
country.
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